 Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid 2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer. 